Alex Marchand-Austin

Alex Marchand-Austin

Auto-generated profile, based on publicly available information

Alex Marchand-Austin

Public Health Ontario, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Emerging Infectious Diseases
Verified
Journal Article
Open access
TMTheodore K. Marras
Theodore K. Marras
DMDavid Mendelson
David Mendelson
AMAlex Marchand-Austin
Alex Marchand-Austin
KMKevin May
Kevin May
FJFrances B. Jamieson
Frances B. Jamieson
We measured the prevalence and temporal trends of pulmonary nontuberculous mycobacterial disease among residents of Ontario, Canada, during 1998–2010. Five-year prevalence increased from 29.3 cases/100,000 persons in 1998–2002 to 41.3/100,000 in 2006–2010 (p<0.0001). Improved laboratory methods did not explain this increase, suggesting a surge in disease prevalence.

24 April 2015 in Thorax
Verified
Journal Article
Open access
PDF file
SBSarah K Brode
Sarah K Brode
FJFrances B Jamieson
Frances B Jamieson
NNNA Ng
NA Ng
MCM. A. Campitelli
M. A. Campitelli
JKJeffrey C Kwong
Jeffrey C Kwong
TMTheodore K Marras
Theodore K Marras
Rationale Anti-tumour necrosis factor (TNF) agents and other anti-rheumatic medications increase the risk of TB in rheumatoid arthritis (RA). Whether they increase the risk of infections with nontuberculous mycobacteria (NTM) is uncertain. Objectives To determine the effect of anti-TNF therapy and other anti-rheumatic drugs on the risk of NTM disease and TB in older patients with RA. Methods Population-based nested case–control study among Ontario seniors aged ≥67 years with RA who were prescribed at least one anti-rheumatic medication between 2001 and 2011. We identified cases of TB and NTM disease microbiologically and identified drug exposures using linked prescription drug claims. We estimated ORs using conditional logistic regression, controlling for several potential confounders. Measurements and main results Among 56 269 older adults with RA, we identified 37 cases of TB and 211 cases of NTM disease; each case was matched to up to 10 controls. Individuals with TB or NTM disease were both more likely to be using anti-TNF therapy (compared with non-use); adjusted ORs (95% CIs) were 5.04 (1.27 to 20.0) and 2.19 (1.10 to 4.37), respectively. Exposure to leflunomide and other anti-rheumatic drugs with high immunosuppressing potential also were associated with both TB and NTM disease, while oral corticosteroids and hydroxychloroquine were associated with NTM disease. Conclusions Anti-TNF use is associated with increased risk of both TB and NTM disease, but appears to be a relatively greater risk for TB. Several other anti-rheumatic drugs were also associated with mycobacterial infections.

26 September 2016 in Canadian Medical Association Journal
Verified
Journal Article
Open access
PDF file
KSKevin L. Schwartz
Kevin L. Schwartz
JKJeffrey C. Kwong
Jeffrey C. Kwong
SDShelley L. Deeks
Shelley L. Deeks
MCMichael A. Campitelli
Michael A. Campitelli
FJFrances B. Jamieson
Frances B. Jamieson
NCNatasha S. Crowcroft
Natasha S. Crowcroft
Background: A resurgence of pertussis cases among both vaccinated and unvaccinated people raises questions about vaccine effectiveness over time. Our objective was to study the effectiveness of the pertussis vaccine and characterize the effect of waning immunity and whole-cell vaccine priming. Methods: We used the test-negative design, a nested case–control study with test-negative individuals as controls. We constructed multivariable logistic regression models to estimate odds ratios (ORs). Vaccine effectiveness was calculated as (1 – OR) × 100. We assessed waning immunity by calculating the odds of developing pertussis per year since last vaccination and evaluated the relative effectiveness of priming with acellular versus whole-cell vaccine. Results: Between Dec. 7, 2009, and Mar. 31, 2013, data on 5867 individuals (486 test-positive cases and 5381 test-negative controls) were available for analysis. Adjusted vaccine effectiveness was 80% (95% confidence interval [CI] 71% to 86%) at 15–364 days, 84% (95% CI 77% to 89%) at 1–3 years, 62% (95% CI 42% to 75%) at 4–7 years and 41% (95% CI 0% to 66%) at 8 or more years since last vaccination. We observed waning immunity with the acellular vaccine, with an adjusted OR for pertussis infection of 1.27 (95% CI 1.20 to 1.34) per year since last vaccination. Acellular, versus whole-cell, vaccine priming was associated with an increased odds of pertussis (adjusted OR 2.15, 95% CI 1.30 to 3.57). Interpretation: We observed high early effectiveness of the pertussis vaccine that rapidly declined as time since last vaccination surpassed 4 years, particularly with acellular vaccine priming. Considering whole-cell vaccine priming and/or boosters in pregnancy to optimize pertussis control may be prudent.

1 March 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
TMTheodore K. Marras
Theodore K. Marras
MCMichael A. Campitelli
Michael A. Campitelli
HLHong Lu
Hong Lu
HCHannah Chung
Hannah Chung
SBSarah K. Brode
Sarah K. Brode
FJFrances B. Jamieson
Frances B. Jamieson
Survival implications of nontuberculous mycobacterial pulmonary disease (NTM-PD) and NTM pulmonary isolation without disease (NTM-PI) are unclear. To study deaths associated with NTM-PD and NTM-PI and differences in survival between them, we conducted a population-based cohort study of persons with microbiologically defined NTM-PD or NTM-PI diagnosed during 2001–2013 in Ontario, Canada. We used propensity score matching and Cox proportional hazards models to compare survival. Among 9,681 NTM-PD patients and 10,936 NTM-PI patients, 87% and 91%, respectively, were successfully matched with unexposed controls. Both NTM-PD and NTM-PI were associated with higher rates of death for all species combined and for most individual species. Compared with NTM-PI, NTM-PD was associated with higher death rates for all species combined, Mycobacterium avium complex, and M. xenopi. NTM-PD and NTM-PI were significantly associated with death, NTM-PD more so than NTM-PI.

1 August 2014 in Anaerobe
Verified
Journal Article
Closed access
AMAlex Marchand-Austin
Alex Marchand-Austin
PRPrasad Rawte
Prasad Rawte
BTBaldwin Toye
Baldwin Toye
FJFrances B. Jamieson
Frances B. Jamieson
DFDavid J. Farrell
David J. Farrell
SPSamir N. Patel
Samir N. Patel

1 September 2014 in Chest
Verified
Journal Article
Closed access
SBSarah K. Brode
Sarah K. Brode
FJFrances B. Jamieson
Frances B. Jamieson
NNNA Ng
NA Ng
MCMichael A. Campitelli
Michael A. Campitelli
JKJeffrey C. Kwong
Jeffrey C. Kwong
TMTheodore K. Marras
Theodore K. Marras